Nitzan Rosenfeld
University of Cambridge
H-index: 51
Europe-United Kingdom
Top articles of Nitzan Rosenfeld
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Ultra-sensitive detection of circulating tumour DNA enriches for patients with greater risk of recurrence in clinically localised prostate cancer | European Urology | Bernard Pope Gahee Park Edmund Lau Jelena Belic Radoslaw Lach | 2024/2/19 |
Author Correction: High-or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial | Nature medicine | Jeroen van Dorp Christodoulos Pipinikas Britt BM Suelmann Niven Mehra Nick van Dijk | 2024/1 |
Highly sensitive method for detecting cancer dna in a sample | 2024/4/25 | ||
High-or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial | Nature medicine | Jeroen van Dorp Christodoulos Pipinikas Britt BM Suelmann Niven Mehra Nick van Dijk | 2023/3 |
Abstract PR012: Ultra-sensitive detection of circulating tumour DNA enriches for patients with higher risk disease in clinically localised prostate cancer | Cancer Research | Bernard J Pope Gahee Park Edmund Lau Jelena Belic Radoslaw Lach | 2023/6/2 |
Enhanced detection of target dna by fragment size analysis | 2023/1/19 | ||
Validation of recurrence prediction using circulating tumor DNA in patients with curatively treated early stage non-small cell lung cancer. | Milou Schuurbiers Christopher Gareth Smith Koen Hartemink Robert Rintoul Kim Monkhorst | 2023/6/1 | |
LIBELULE: a randomized phase III study to evaluate the clinical relevance of early liquid biopsy in patients with suspicious metastatic lung cancer | Aurélie Swalduz Hubert Curcio Bana Ambasager Gabriel Le Moel Didier Debieuvre | 2023 | |
Integrated radiogenomics models predict response to neoadjuvant chemotherapy in high grade serous ovarian cancer | Nature communications | Mireia Crispin-Ortuzar Ramona Woitek Marika AV Reinius Elizabeth Moore Lucian Beer | 2023/10/24 |
Multimodal detection in plasma of molecular residual disease (MRD) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC). | Enrique Sanz Garcia Jinfeng Zou Lisa Avery Anna Spreafico John Waldron | 2023/6/1 | |
Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer | nature communications | RC Coombes PD Badman JP Lozano-Kuehne X Liu IR Macpherson | 2023 |
235TiP Hamlet. rt Trans: Prospective single-centre translational study evaluating liquid biomarkers of radiation response | Annals of Oncology | M Denholm HW Martin A Roshan S Miller G Harden | 2023/10/1 |
Circulating tumor DNA (ctDNA) monitoring in patients with breast cancer receiving neoadjuvant palbociclib and endocrine therapy: A secondary analysis of the NeoRHEA phase 2 study. | Alexandra Stanciu Andreas Papagiannis Christodoulos Pipinikas Nathan Campbell Mariana Brandão | 2023/6/1 | |
Comparison of tumor‐informed and tumor‐naïve sequencing assays for ctDNA detection in breast cancer | EMBO molecular medicine | Angela Santonja Wendy N Cooper Matthew D Eldridge Paul AW Edwards James A Morris | 2023/6/7 |
A large-scale retrospective study in metastatic breast cancer patients using circulating tumor DNA and machine learning to predict treatment outcome and progression-free survival | bioRxiv | Emma J Beddowes Mario Ortega-Duran Solon Karapanagiotis Alistair Martin Meiling Gao | 2023/3/3 |
Abstract P2-01-07: Detection of early-stage breast cancer recurrence using a personalised liquid biopsy-based sequencing approach | Cancer Research | Wolfgang Janni Jens Huober Sophia Huesmann Christodoulos Pipinikas Tatjana Braun | 2022/2/15 |
Predicting pathological response after ipilimumab plus nivolumab in stage III urothelial cancer by liquid biopsy assessment of plasma and urine ctDNA using the RaDaR assay | Jeroen van Dorp Christodoulos Pipinikas Nick van Dijk Greg Jones Alberto Gil-Jimenez | 2022/6/15 | |
Refined characterization of circulating tumor DNA through biological feature integration | Scientific reports | Havell Markus Dineika Chandrananda Elizabeth Moore Florent Mouliere James Morris | 2022/2/4 |
Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer | Nature communications | RC Coombes PD Badman JP Lozano-Kuehne X Liu Iain R Macpherson | 2022/6/10 |
Characteristics, origin, and potential for cancer diagnostics of ultrashort plasma cell-free DNA | Genome research | Irena Hudecova Christopher G Smith Robert Hänsel-Hertsch Chandra S Chilamakuri James A Morris | 2022/2/1 |
